Sentante has unveiled a new precision-controlled digital indeflator—dubbed ‘Inflante’—that is designed to modernise balloon inflation, improving clinical control and procedural consistency in the process. As a digital subsystem, Inflante contributes pressure profiles, inflation timing and procedural state to the multimodal data layer that the broader Sentante robotic platform records, according to the company.
This new system is intended to replace the traditional, manual indeflator—a widely deployed balloon inflation tool used in procedures like angioplasties and stent deployments—with a digitally controlled interface offering repeatability and real-time feedback. A press release details that this launch marks a key step in Sentante’s strategy to digitise the cath lab, complementing its robotic platform and signifying advancement toward a fully integrated, data-driven workflow.
“Precision in pressure control is fundamental,” said Tomas Baltrunas, Sentante’s co-founder and chief medical officer. “Digitising this process improves control today while enabling better learning and outcomes over time.”
Sentante goes on to note that, despite its centrality to a number of endovascular procedures, balloon inflation remains an analogue, manual process with “limited precision and no structured data capture”.
With this in mind, Inflante introduces digital pressure control with high-resolution adjustment; real-time feedback and monitoring; and integrated data capture—pressure profiles, inflation timing and procedural state—feeding the multimodal substrate that Sentante’s broader Physical artificial intelligence (AI) roadmap consumes. Additionally, by reducing manual variability, the system aims to improve outcomes while lowering clinician cognitive load.
“Endovascular procedures are still full of analogue steps that introduce variability,” commented Edvardas Satkauskas, co-founder and chief executive officer (CEO) of Sentante. “A digital indeflator transforms one of those steps into a precise, data-rich process within a fully digital ecosystem.”
Sentante’s release states that manual indeflators require continuous operation and interpretation, increasing workload and risk of inconsistency. Meanwhile, the company’s new system enables:
- More stable inflation, reducing over- or under-pressurisation risk
- Reduced manual strain, allowing focus on decision-making
- Improved reproducibility for training and standardisation
“Every step we digitise is a step toward more consistent, scalable and accessible treatment,” Satkauskas added.
Inflante is being developed both as a standalone tool and as part of Sentante’s robotic platform, supporting future remote and semi-autonomous procedures. In the company’s view, the future will see digitised subsystems capable of enabling remote interventions, closed-loop procedural control, and AI-assisted workflows.
Inflante is CE marked in Europe, and is currently progressing through US Food and Drug Administration (FDA) regulatory pathways as a standalone device.
